About this trial
This study is looking at the safety, tolerability and efficacy of elvitegravir, a new protease inhibitor, boosted with ritonavir.
They are comparing the drug to the newly approved integrase inhibitor - raltegravir.
People who are treatment experienced will be given either drug with a background regimen including another protease inhibitor.
| Official title: | A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults |
|---|---|
| What is this trial studying? | New drug |
| Start date: | August 2008 This may be the proposed or expected start date for trials which have not yet started. |
| How many participants will this trial enrol? | 700 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
| How long is this trial planned to go for? | Participants in this trial will be asked to take the trial drug for 48 weeks. |
| Who can enrol in this trial? | You may be eligible to participate in this trial if you meet the following criteria:
|
| Links to further information: | |
| Keywords: | elvitegravir, raltegravir, ritonavir |
If you are interested in enrolling in this trial
Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.
- You can print this page to take it with you to the doctor – just use your browser's 'print' function.
- Before making the decision to participate in any clinical research, read our background information.
- Email NAPWA if you have any questions or comments about this trial
- Call the Treataware info line if you need further advice
If you've ever participated in a clinical trial, or tried to make sense of scientific research reports, you may have found some of the specialised language confusing to say the least. This Backgrounder (from the Nov-Dec 2002 edition of Positive Living) looks at the vocabulary of clinical trials.